Tumor imaging with technetium-99m-labeled hydrazinonicotinamide-Fab' conjugates

Area of Science:

• Bioconjugation Chemistry
• Radiopharmaceutical Development
• Immunohistochemistry

Background:

• Antibody fragments are crucial for targeted cancer therapy and diagnostics.
• Radiolabeling methods impact the in vivo behavior and imaging efficacy of antibody fragments.
• Direct and indirect labeling strategies offer different approaches for attaching radioisotopes.

Purpose of the Study:

• To compare the in vivo properties of direct versus indirect 99mTc-labeling for antibody fragments targeting tumor-associated antigens.
• To evaluate the impact of labeling method on tumor accumulation, blood clearance, and imaging quality.
• To determine the optimal labeling strategy for enhanced tumor visualization.

Main Methods:

• Fab' fragments of monoclonal antibodies were site-specifically conjugated with bromoacetyl hydrazinonicotinamide hydrobromide (BAHNH) for indirect labeling.
• Direct and indirect preparations were labeled with technetium-99m (99mTc) to >95% incorporation.
• Labeled fragments were administered to tumor-bearing mice, with analysis of tissue distribution at 4 and 24 hours post-injection and gamma scintigraphy.

Main Results:

• Indirectly labeled fragments showed significantly greater isotope accumulation in tumors compared to directly labeled fragments (1.5- to 3.2-fold increase).
• Blood clearance was similar for both labeling methods, leading to improved tumor-to-blood ratios with indirect labeling.
• Tumor imaging was clearer and more sensitive at 24 hours with indirectly labeled fragments.

Conclusions:

• Indirect 99mTc-labeling of antibody fragments enhances tumor accumulation and improves tumor-to-blood ratios.
• Indirect labeling provides superior imaging clarity and sensitivity for tumor detection compared to direct labeling.
• The findings support indirect labeling as a preferred method for developing effective radiopharmaceuticals for cancer imaging.